Ameritas Investment Partners
ALLO icon

Ameritas Investment Partners’s Allogene Therapeutics ALLO Stock Holding History

Ameritas Investment Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.2K Buy
24,113
+11,083
+85% +$24.3K ﹤0.01% 2255
2026
Q1 		$31.8K Hold
13,030
– – ﹤0.01% 2361
2025
Q4 		$17.9K Hold
13,030
– – ﹤0.01% 2687
2025
Q3 		$16.2K Buy
13,030
+26
+0.2% +$31 ﹤0.01% 2765
2025
Q2 		$14.7K Hold
13,004
– – ﹤0.01% 2811
2025
Q1 		$19K Hold
13,004
– – ﹤0.01% 2581
2024
Q4 		$27.7K Hold
13,004
– – ﹤0.01% 2492
2024
Q3 		$36.4K Buy
13,004
+4,900
+60% +$13.1K ﹤0.01% 2370
2024
Q2 		$18.9K Hold
8,104
– – ﹤0.01% 2642
2024
Q1 		$36.2K Hold
8,104
– – ﹤0.01% 2306
2023
Q4 		$26K Hold
8,104
– – ﹤0.01% 2468
2023
Q3 		$25.7K Buy
8,104
+2,067
+34% +$9.06K ﹤0.01% 2427
2023
Q2 		$30K Hold
6,037
– – ﹤0.01% 2333
2023
Q1 		$29.8K Hold
6,037
– – ﹤0.01% 2276
2022
Q4 		$41.4K Hold
6,037
– – ﹤0.01% 2194
2022
Q3 		$65K Hold
6,037
– – ﹤0.01% 1785
2022
Q2 		$68K Buy
6,037
+705
+13% +$6.26K ﹤0.01% 1777
2022
Q1 		$49K Hold
5,332
– – ﹤0.01% 2064
2021
Q4 		$80K Hold
5,332
– – ﹤0.01% 1815
2021
Q3 		$137K Hold
5,332
– – 0.01% 1493
2021
Q2 		$139K Buy
5,332
+738
+16% +$21K 0.01% 1517
2021
Q1 		$162K Hold
4,594
– – 0.01% 1344
2020
Q4 		$116K Hold
4,594
– – 0.01% 1493
2020
Q3 		$173K Buy
4,594
+309
+7% +$11.7K 0.01% 1108
2020
Q2 		$183K Buy
4,285
+934
+28% +$33.8K 0.01% 1059
2020
Q1 		$65K Hold
3,351
– – ﹤0.01% 1518
2019
Q4 		$87K Hold
3,351
– – ﹤0.01% 1595
2019
Q3 		$91K Hold
3,351
– – ﹤0.01% 1527
2019
Q2 		$90K Buy
3,351
+1,588
+90% +$44.2K ﹤0.01% 1560
2019
Q1 		$51K Hold
1,763
– – ﹤0.01% 1866
2018
Q4 		$47K Buy
+1,763
New +$46.8K ﹤0.01% 1844

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPG GP A
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Ameritas Investment Partners's ALLO Position: Q2 2026 in Review

Ameritas Investment Partners increased its Allogene Therapeutics (ALLO) stake by 85% in Q2 2026, buying an estimated $24.3K and bringing the position to 24,113 shares worth $50.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2255.

Ameritas Investment Partners first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $183K in Q2 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Ameritas Investment Partners held 24,113 shares of Allogene Therapeutics worth $50.2K as of Q2 2026.
  • Ameritas Investment Partners bought 11,083 Allogene Therapeutics shares in Q2 2026, an estimated $24.3K.
  • Allogene Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2255 holding.
  • Ameritas Investment Partners first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Ameritas Investment Partners's Allogene Therapeutics position peaked at $183K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.